留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

新型冠状病毒肺炎与甲状腺疾病

陈紫晗 李乃适 连小兰

陈紫晗, 李乃适, 连小兰. 新型冠状病毒肺炎与甲状腺疾病[J]. 协和医学杂志, 2022, 13(3): 487-492. doi: 10.12290/xhyxzz.2021-0791
引用本文: 陈紫晗, 李乃适, 连小兰. 新型冠状病毒肺炎与甲状腺疾病[J]. 协和医学杂志, 2022, 13(3): 487-492. doi: 10.12290/xhyxzz.2021-0791
CHEN Zihan, LI Naishi, LIAN Xiaolan. Coronavirus Disease 2019 and Thyroid Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 487-492. doi: 10.12290/xhyxzz.2021-0791
Citation: CHEN Zihan, LI Naishi, LIAN Xiaolan. Coronavirus Disease 2019 and Thyroid Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 487-492. doi: 10.12290/xhyxzz.2021-0791

新型冠状病毒肺炎与甲状腺疾病

doi: 10.12290/xhyxzz.2021-0791
基金项目: 

中国医学科学院医学与健康科技创新工程 2021-1-I2M-022

详细信息
    通讯作者:

    李乃适, E-mail:lns@medmail.com.cn

  • 中图分类号: R581

Coronavirus Disease 2019 and Thyroid Diseases

Funds: 

CAMS Innovation Fund for Medical Sciences 2021-1-I2M-022

More Information
  • 摘要: 自新型冠状病毒肺炎(coronavirus disease 2019, COVID-19)疫情暴发以来, 出现了若干COVID-19相关甲状腺疾病的报道, 包括亚急性甲状腺炎、自身免疫性甲状腺疾病、非甲状腺疾病综合征以及原因未明的甲状腺功能异常。本综述旨在对COVID-19相关甲状腺疾病的临床特点进行总结, 并探究可能的发生机制。
    作者贡献:李乃适、连小兰负责构思论文;陈紫晗负责查阅文献资料和撰写论文;李乃适、连小兰、陈紫晗负责修订论文。
    利益冲突:所有作者均声明不存在利益冲突
  • 表  1  COVID-19伴发GD的病例特点

    病例 年龄
    (岁)
    性别 前驱时间
    (周)*
    既往GD病史 TSH FT3 FT4 TRAb TPOAb 甲状腺放射性碘摄取率 治疗 参考文献
    病例1 21 2 + NR NR MMI+β-RB Harris等[13]
    病例2 45 8 有,已恢复正常2年 NR + NR NR MMI Jiménez-Blanco等[14]
    病例3 61 4 有,已恢复正常4年 NR + NR MMI Jiménez-Blanco等[14]
    病例4 60 5 有,已恢复正常35年 正常范围 + + MMI+β-RB Mateu-Salat等[15]
    病例5 53 9 + + MMI+β-RB Mateu-Salat等[15]
    *发现SARS-CoV-2感染至确诊GD的时间;NR:文献中未提及;COVID-19:新型冠状病毒肺炎;GD:Graves病;TSH:促甲状腺激素;FT3:游离三碘甲状腺原氨酸;FT4:游离甲状腺素;TRAb:促甲状腺激素受体抗体;TPOAb:抗甲状腺过氧化物酶抗体; MMI: 甲巯咪唑;β-RB:β受体阻滞剂
    下载: 导出CSV
  • [1] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8: 475-481. doi:  10.1016/S2213-2600(20)30079-5
    [2] Ge H, Wang X, Yuan X, et al. The epidemiology and clinical information about COVID-19[J]. Eur J Clin Microbiol Infect Dis, 2020, 39: 1011-1019. doi:  10.1007/s10096-020-03874-z
    [3] Doustmohammadian S, Doustmohammadian A, Momeni M. Association between thyroid disorders and COVID-19: a protocol for a systematic review and meta-analysis[J]. Thyroid Res, 2021, 14: 21. doi:  10.1186/s13044-021-00113-1
    [4] Pearce EN, Farwell AP, Braverman LE. Thyroiditis[J]. N Engl J Med, 2003, 348: 2646-2655. doi:  10.1056/NEJMra021194
    [5] Desailloud R, Hober D. Viruses and thyroiditis: an update[J]. Virol J, 2009, 6: 5. doi:  10.1186/1743-422X-6-5
    [6] Brancatella A, Ricci D, Viola N, et al. Subacute Thyroiditis After SARS-CoV-2 Infection[J]. J Clin Endocrinol Metab, 2020, 105: dgaa276. doi:  10.1210/clinem/dgz049
    [7] Caron P. Thyroiditis and SARS-CoV-2 pandemic: a review[J]. Endocrine, 2021, 72: 326-331. doi:  10.1007/s12020-021-02689-y
    [8] Inaba H, Aizawa T. Coronavirus Disease 2019 and the Thyroid-Progress and Perspectives[J]. Front Endocrinol(Lausanne), 2021, 12: 708333. doi:  10.3389/fendo.2021.708333
    [9] Ippolito S, Dentali F, Tanda ML. SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report[J]. J Endocrinol Invest, 2020, 43: 1171-1172. doi:  10.1007/s40618-020-01312-7
    [10] Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19[J]. Nat Rev Rheumatol, 2020, 16: 413-414. doi:  10.1038/s41584-020-0448-7
    [11] Testa A, Castaldi P, Fant V, et al. Prevalence of HCV Antibodies in Autoimmune Thyroid Disease[J]. Eur Rev Med Pharmacol Sci, 2006, 10: 183-186.
    [12] Sultanova A, Cistjakovs M, Gravelsina S, et al. Association of Active Human Herpesvirus-6 (HHV-6) Infection With Autoimmune Thyroid Gland Diseases[J]. Clin Microbiol Infect, 2017, 23: 50 e51-50 e55.
    [13] Harris A, Al Mushref M. Graves' Thyrotoxicosis Following SARS-CoV-2 Infection[J]. AACE Clin Case Rep, 2021, 7: 14-16. doi:  10.1016/j.aace.2020.12.005
    [14] Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves' hyperthyroidism? [J]. J Endocrinol Invest, 2021, 44: 387-388. doi:  10.1007/s40618-020-01440-0
    [15] Mateu-Salat M, Urgell E, Chico A. SARS-CoV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19[J]. J Endocrinol Invest, 2020, 43: 1527-1528. doi:  10.1007/s40618-020-01366-7
    [16] Tee LY, Hajanto S, Rosario BH. COVID-19 Complicated by Hashimoto's Thyroiditis[J]. Singapore Med J, 2021, 62: 265. doi:  10.11622/smedj.2020106
    [17] Fliers E, Boelen A. An update on non-thyroidal illness syndrome[J]. J Endocrinol Invest, 2021, 44: 1597-1607. doi:  10.1007/s40618-020-01482-4
    [18] Zou R, Wu C, Zhang S, et al. Euthyroid Sick Syndrome in Patients With COVID-19[J]. Front Endocrinol (Lausanne), 2020, 11: 566439. doi:  10.3389/fendo.2020.566439
    [19] Khoo B, Tan T, Clarke SA, et al. Thyroid Function Before, During, and After COVID-19[J]. J Clin Endocrinol Metab, 2021, 106: e803-e811. doi:  10.1210/clinem/dgaa830
    [20] Shabana TS, Anis SG, Ibrahim DM. Association between Thyroid Dysfunction and Intensive Care Unit-Acquired Weakness: A Case-Control Study[J]. Crit Care Res Pract, 2021, 2021: 8889036.
    [21] Wang W, Su X, Ding Y, et al. Thyroid function abnormalities in COVID-19 patients[J]. Front Endocrinol (Lausanne), 2020, 11: 623792.
    [22] Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19: a retrospective study[J]. Thyroid, 2020, 31: 8-11.
    [23] Lania A, Sandri MT, Cellini M, et al. Thyrotoxicosis in patients with COVID-19: the Thyrcov study[J]. Eur J Endocrinol, 2020, 183: 381-387. doi:  10.1530/EJE-20-0335
    [24] Gao W, Guo W, Guo Y, et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19[J]. J Endocrinol Invest, 2021, 44: 1031-1040. doi:  10.1007/s40618-020-01460-w
    [25] Campi I, Bulgarelli I, Dubini A, et al. The spectrum of thyroid function tests during hospitalization for SARS-CoV-2 infection[J]. Eur J Endocrinol, 2021, 184: 699-709. doi:  10.1530/EJE-20-1391
    [26] Güven M, Gültekin H. The prognostic impact of thyroid disorders on the clinical severity of COVID-19: results of single-centre pandemic hospital[J]. Int J Clin Pract, 2021, 75: e14129.
    [27] Daraei M, Hasibi M, Abdollahi H, et al. Possible role of hypothyroidism in the prognosis of COVID-19[J]. Intern Med J, 2020, 50: 1410-1412. doi:  10.1111/imj.15000
    [28] Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis[J]. Lancet Diabetes Endocrinol, 2020, 8: 739-741. doi:  10.1016/S2213-8587(20)30266-7
    [29] Lam SD, Bordin N, Waman VP, et al. SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals[J]. Sci Rep, 2020, 10: 16471. doi:  10.1038/s41598-020-71936-5
    [30] Li MY, Li L, Zhang Y, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J]. Infect Dis Poverty, 2020, 9: 45. doi:  10.1186/s40249-020-00662-x
    [31] Rotondi M, Coperchini F, Ricci G, et al. Detection of SARS-CoV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis[J]. J Endocrinol Invest, 2021, 44: 1085-1090. doi:  10.1007/s40618-020-01436-w
    [32] Moore JB, June CH. Cytokine release syndrome in severe COVID-19[J]. Science, 2020, 368: 473-474. doi:  10.1126/science.abb8925
    [33] Turner AJ, Tipnis SR, Guy JL, et al. Aceh/Ace2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ace inhibitors[J]. Can J Physiol Pharmacol, 2002, 80: 346-353. doi:  10.1139/y02-021
    [34] Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2[J]. Antiviral Res, 2020, 177: 104759. doi:  10.1016/j.antiviral.2020.104759
    [35] Luan J, Lu Y, Gao S, et al. A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2[J]. J Infect, 2020, 81: 318-356.
    [36] Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19[J]. Nat Immunol, 2020, 21: 1336-1345. doi:  10.1038/s41590-020-0782-6
    [37] Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis[J]. Rev Med Virol, 2020, 30: 1-9.
    [38] Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19[J]. Nature, 2020, 583: 437-440. doi:  10.1038/s41586-020-2355-0
    [39] Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type Ⅰ interferons in development of severe COVID-19[J]. Sci Immunol, 2020, 5: eabd1554. doi:  10.1126/sciimmunol.abd1554
    [40] Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19[J]. Nature, 2020, 584: 463-469. doi:  10.1038/s41586-020-2588-y
    [41] Melo Silva Junior ML, Souza LMA, Dutra R, et al. Review on therapeutic targets for COVID-19: insights from cytokine storm[J]. Postgrad Med J, 2021, 97: 391-398. doi:  10.1136/postgradmedj-2020-138791
    [42] Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection[J]. Diabetes Metab Syndr, 2020, 14: 1429-1430. doi:  10.1016/j.dsx.2020.07.044
    [43] Caron P. Thyroid disorders and SARS-CoV-2 infection: from pathophysiological mechanism to patient management[J]. Ann Endocrinol (Paris), 2020, 81: 507-510. doi:  10.1016/j.ando.2020.09.001
    [44] Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease[J]. Immunol Res, 2012, 54: 191-203. doi:  10.1007/s12026-012-8312-8
    [45] Kawashima A, Yamazaki K, Hara T, et al. Demonstration of innate immune responses in the thyroid gland: potential to sense danger and a possible trigger for autoimmune reactions[J]. Thyroid, 2013, 23: 477-487. doi:  10.1089/thy.2011.0480
    [46] Lisco G, De Tullio A, Jirillo E, et al. Thyroid and COVID-19: a review on pathophysiological, clinical and organiza-tional aspects[J]. J Endocrinol Invest, 2021, 44: 1801-1814. doi:  10.1007/s40618-021-01554-z
  • 加载中
表(1)
计量
  • 文章访问数:  168
  • HTML全文浏览量:  9
  • PDF下载量:  36
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-12-15
  • 录用日期:  2021-12-27
  • 网络出版日期:  2021-12-30
  • 刊出日期:  2022-05-30

目录

    /

    返回文章
    返回

    【通知】尊敬的读者、作者及编者:因特殊原因,本站自2022.9.30至10.24日期间实施6—24点开放,其他时段访问受限,给您带来不便敬请谅解!10.25日恢复如常。